| 11.83 0.11 (0.94%) | 04-24 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.65 | 1-year : | 17.95 |
| Resists | First : | 13.4 | Second : | 15.36 |
| Pivot price | 11.94 |
|||
| Supports | First : | 10.21 | Second : | 8.49 |
| MAs | MA(5) : | 11.46 |
MA(20) : | 12.32  |
| MA(100) : | 10.76 |
MA(250) : | 9.17 |
|
| MACD | MACD : | -0.6 |
Signal : | -0.5 |
| %K %D | K(14,3) : | 38 |
D(3) : | 26.9 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 17.51 | Low : | 3.72 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ PEPG ] has closed above bottom band by 44.9%. Bollinger Bands are 43% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 0 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 11.98 - 12.03 | 12.03 - 12.08 |
| Low: | 11.17 - 11.23 | 11.23 - 11.28 |
| Close: | 11.74 - 11.83 | 11.83 - 11.91 |
PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Thu, 25 Apr 2024
New Strong Buy Stocks for April 25th - Yahoo Finance Australia
Sat, 20 Apr 2024
PepGen Inc.'s (NASDAQ:PEPG) market cap dropped US$79m last week; individual investors who hold 48% were hit as ... - Simply Wall St
Tue, 12 Mar 2024
Can PepGen, Inc. (PEPG) Climb 48.62% to Reach the Level Wall Street Analysts Expect? - Yahoo Finance
Mon, 11 Mar 2024
PepGen, Inc. (PEPG) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Thu, 07 Mar 2024
PepGen, Inc. (PEPG) Q4 2023 Earnings Call Transcript - Seeking Alpha
Wed, 06 Mar 2024
PEPG Stock Earnings: PepGen Beats EPS for Q4 2023 - InvestorPlace
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 32 (M) |
| Shares Float | 17 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 76.7 (%) |
| Shares Short | 400 (K) |
| Shares Short P.Month | 214 (K) |
| EPS | -3.3 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.55 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -29.4 % |
| Return on Equity (ttm) | -54.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -2.59 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -69 (M) |
| Levered Free Cash Flow | -44 (M) |
| PE Ratio | -3.59 |
| PEG Ratio | 0 |
| Price to Book value | 2.59 |
| Price to Sales | 0 |
| Price to Cash Flow | -5.55 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|